top of page
Leading the Way in Intratumoral Radiotherapeutics
News
Categories
Sign up
Featured Posts
Archive
Follow Us
ATM Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility
JERUSALEM, October 30, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
Oct 30, 2023
Former U.S. Commissioner of FDA Stephen M. Hahn, M.D. Appointed to Alpha Tau Advisory Board
JERUSALEM, October 24, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
Oct 24, 2023
Alpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Hadassah Medical Center
JERUSALEM, Sept. 14, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
Sep 14, 2023
Alpha Tau Medical Announces Second Quarter 2023 Financial Results and Provides Corporate Update
– Treated the first patient with advanced inoperable pancreatic cancer in a safety and feasibility trial in Canada in April – – 89% CR,...
Aug 29, 2023
Alpha Tau Medical to Participate in September Investor Conferences
JERUSALEM, August 24, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
Aug 24, 2023
Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha
- 81 lesions treated across four feasibility trials of head and neck or skin cancers demonstrated 89% complete response rate. - Two-year...
Aug 21, 2023
Alpha Tau Medical to Present at the Emerging Growth Conference on August 9th, 2023
JERUSALEM, August 02, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
Aug 2, 2023
Alpha Tau Medical to Participate in June Investor Conferences
JERUSALEM, May 24, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative...
May 25, 2023
Alpha Tau Medical Announces First Quarter 2023 Financial Results and Provides Corporate Update
- Opened U.S. multicenter pivotal trial in recurrent cutaneous skin cancer, which began enrolling patients in March - - Treated the first...
May 24, 2023
Alpha Tau Announces Publication: US Multicenter Pilot Skin Cancer Trial Results in JAMA Network Open
- The trial demonstrated a 100% Complete Response rate at 12 weeks post treatment and no device-related serious adverse events or...
May 12, 2023
bottom of page